You are on page 1of 3

Global Multiple Sclerosis Treatment Market US$ 22.

8 Billion by 2021

The global multiple sclerosis drugs market to reach US$ 22.8 billion by 2021, steadily growing at CAGR 0.7% during
forecast period 2017-2021, mainly due to large number of both existing therapeutics and
new entrants.

Multiple sclerosis (MS) is a leading cause of neurological disability among young adults. Although the precise causes
of MS remain unknown, the disease is characterized by an autoimmune reaction against myelin, the fatty insulation
that surrounds nerve cells. MS is highly heterogeneous, but has three main subtypes: relapsing forms of MS (RFMS),
primary progressive MS (PPMS) and progressive relapsing MS (PRMS). Worldwide, MS affects ~2.3 million people,
where the majority of patients (~85%) have RFMS, 10% have PPMS, and 5% have PRMS. Treatment typically focuses
on speeding recovery from attacks, slowing the progression of the disease and managing MS symptoms.

Treatment for MS depends on the specific symptoms and difficulties the person has. It may include: treating relapses
of MS symptoms (with steroid medication), treating specific MS symptoms, and treatment to reduce the number of
relapses (disease-modifying therapies). Treatment options for relapsing-remitting MS include: Beta interferons are
among the most commonly prescribed medications to treat MS and can reduce the frequency and severity of
relapses. Glatiramer acetate (Copaxone) may help block your immune system's attack on myelin. Dimethyl fumarate
(Tecfidera) can reduce relapses. Fingolimod (Gilenya) and Teriflunomide (Aubagio) oral medications reduces relapse
rate. Natalizumab (Tysabri) blocks the movement of potentially damaging immune cells from your bloodstream to
your brain and spinal cord. Alemtuzumab (Lemtrada) drug helps reduce relapses of MS by targeting a protein on the
surface of immune cells and depleting white blood cells. In 2016, all of the available disease-modifying treatments
for MS were approved for relapsing forms of the disease, and no treatment options existed for PPMS.

Browse Multiple Sclerosis Treatment Market by Drug Class (Brand) - Alemtuzumab (Lemtrada), Dimethyl Fumarate
(Tecifidera), Gilneya (Fingolimod), Glatiramer Acetate (Copaxone), Interferon-1a (Avonex), Interferon-1a (Rebif),
Interferon-1b (Betaseron/Extavia), Natalizumab (Tysabri), Peginterferon-1a (Plegridy), Teriflunomide (Aubagio),
Clinical Pipeline (Phase III) - Daclizumab (Zinbryta), Ocrelizumab (Ocrevus), Ozanimod (RPC-1063) and Forecast
2017-2021 at https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/

The global multiple sclerosis treatment market report provides market size (Revenue USD Million 2014 to 2021),
market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global multiple sclerosis treatment
market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil,
Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. The global multiple sclerosis treatment market report also provides the detailed
market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the
major competitors operating in the market by company overview, financial snapshot, key products, technologies
and services offered, market share analysis and recent trends in the global market.

Major players operating in the global multiple sclerosis drugs market and included in this report are Actelion, arGEN-
x, Bayer Healthcare, Biogen Idec, Celgene, GeNeuro, Innate Immunotherapeutics, InnoBioscience, Merck, Novartis,
Opexa Therapeutics, Pfizer, Sanofi-Aventis, Teva Pharmaceuticals, and TG Therapeutics.

1. Drug Class (Brand)


1.1. Alemtuzumab (Lemtrada)
1.2. Dimethyl Fumarate (Tecifidera)
1.3. Gilneya (Fingolimod)
1.4. Glatiramer Acetate (Copaxone)
1.5. Interferon-1a (Avonex)
1.6. Interferon-1a (Rebif)
1.7. Interferon-1b (Betaseron/Extavia)
1.8. Natalizumab (Tysabri)
1.9. Peginterferon-1a (Plegridy)
1.10. Teriflunomide (Aubagio)

2. Clinical Pipeline (Phase III)


2.1. Daclizumab (Zinbryta)
2.2. Ocrelizumab (Ocrevus)
2.3. Ozanimod (RPC-1063)

3. Geography (Region, Country)


3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Asia Pacific (Japan, China, India, Rest of APAC)
3.4. Latin America (Brazil, Mexico, Rest of LA)
3.5. Rest of the World

4. Company Profiles
4.1. Actelion
4.2. arGEN-x
4.3. Bayer Healthcare
4.4. Biogen Idec
4.5. Celgene
4.6. GeNeuro
4.7. Innate Immunotherapeutics
4.8. InnoBioscience
4.9. Merck
4.10. Novartis
4.11. Opexa Therapeutics
4.12. Pfizer
4.13. Sanofi-Aventis
4.14. Teva Pharmaceuticals
4.15. TG Therapeutics

To request Table of Contents and Sample Pages of this report visit:


https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/

About Us

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting
grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client
assignments targeted at clients specific business objectives, information needs, time frame and budget. Please
contact us to receive a proposal for a proprietary single-client study.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com